Ethical considerations of biomarker use in neurodegenerative diseases-A case study of Alzheimer's disease

Progress in Neurobiology

Volumn 95, Issue 4, 2011, Pages 517-519

  Prvulovic, David ^a   Hampel, Harald ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Biomarkers; Ethics; Genetic test; IRB; Neurodegenerative diseases; Regulatory authorities

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CLINICAL FEATURE; DISEASE COURSE; EARLY DIAGNOSIS; ETHICS; HUMAN; NOTE; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT AUTONOMY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SOCIAL ASPECT; SYMPTOM;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; ETHICISTS; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 82755187525     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.11.009     Document Type: Note

References (14)

1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
2. Baker L.D., Frank L.L., Foster-Schubert K., Green P.S., Wilkinson C.W., McTiernan A., Plymate S.R., Fishel M.A., Watson G.S., Cholerton B.A., Duncan G.E., Mehta P.D., Craft S. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch. Neurol. 2010, 67:71-79.
3. Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994, 330:585-591.
4. Delrieu J., Piau A., Caillaud C., Voisin T., Vellas B. Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy. CNS Drugs 2011, 25:213-226.
5. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
6. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
7. Ewers M., Sperling R.A., Klunk W.E., Weiner M.W., Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 2011, 34. 430-342.
8. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., Sanhai W.R., Zetterberg H., Woodcock J., Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010, 9:560-574.
9. Lim W.S., Rubin E.H., Coats M., Morris J.C. Early-stage Alzheimer disease represents increased suicidal risk in relation to later stages. Alzheimer Dis. Assoc. Disord. 2005, 19:214-219.
10. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
11. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
12. Mendez M.F., Shapira J.S., McMurtray A., Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am. J. Geriatr. Psychiatry 2007, 15(January (1)):84-87.
13. Porteri C., Galluzzi S., Geroldi C., Frisoni G.B. Diagnosis disclosure of prodromal Alzheimer disease-ethical analysis of two cases. Can. J. Neurol. Sci. 2010, 37:67-75.
14. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.